Dyslipidemia characterized by high plasma triglycerides and low HDL-cholesterol is a key risk factor for cardiovascular disease. There are approximately 150 million people with this type of dyslipidemia in the G7 countries and 60 million of them are considered as high-risk patients. Lipigon Pharmaceuticals develops innovative first-in-class drugs aiming at treating these patients.
Lipigon Pharmaceuticals AB
Lipigon is a lipid biology specialist company, utilizing its proprietary and unique know-how and technologies to discover and develop novel therapies for patients with lipid disorders and other cardiometabolic risk factors.